Lionco(SH:603669) Shang Hai Zheng Quan Bao·2025-12-30 23:34Core Viewpoint - The company has announced a "Quality Improvement and Efficiency Enhancement Action Plan" aimed at enhancing operational quality, market competitiveness, and investor returns in response to regulatory initiatives and market conditions [1]. Group 1: Operational Focus - The company will concentrate on its core business, aiming to improve operational quality and efficiency by reducing costs and expanding market presence in the "big health" industry [1][2]. - The company plans to leverage opportunities from national procurement policies to increase market share of selected products and ensure stable supply in designated regions [2]. Group 2: Innovation and Product Development - The company aims to strengthen its product line by enhancing research and development capabilities, focusing on high-difficulty generics and innovative drugs, and collaborating with renowned research institutions [4]. - The company will accelerate the launch of new products and optimize resource allocation for ongoing projects, ensuring a dynamic evaluation of existing products for market potential [4]. Group 3: Investor Relations and Returns - The company has distributed a total of 607 million yuan in dividends since its listing in 2015 and plans to enhance investor returns through increased dividend frequency and ratios [5]. - The company emphasizes transparent communication with investors through various channels, including shareholder meetings and performance briefings, to foster a better understanding of its operations [5][6]. Group 4: Governance and Compliance - The company is committed to adhering to regulatory requirements and improving its governance structure to protect the interests of all shareholders, particularly minority investors [6][7]. - The company will enhance the compliance awareness of its key personnel and ensure effective risk management through various supervisory mechanisms [7]. Group 5: Strategic Development - The company will utilize the advantages of the Hainan Free Trade Port to develop a collaborative industrial system and enhance production efficiency through partnerships and contract manufacturing [3]. - The company aims to integrate digital and intelligent technologies into its operations to drive innovation in drug development and production processes [2][3].